Copy to clipboard 
Evonik is moving its North America headquarters from Parsippany, New Jersey to Piscataway, New Jersey. The official address change took effect on January 1, 2023. The Parsippany location will be closed with the end of its lease later this year.
The relocation is part of Evonik’s larger site rationalization plan to ensure efficient operations and future growth in North America. Evonik has embraced a hybrid work model in the region to consolidate office space, enhance employee engagement and increase employer attractiveness.
The new Piscataway headquarters, located approximately 35 miles southwest of New York City, consists of administrative offices, laboratories for Research & Development, and a Collaboration Hub in the North America region – designed to support a hybrid and creative work environment for more than 160 employees. Evonik has recently opened similar hubs at its sites in Richmond, Virginia and Mobile, Alabama, and will eventually feature them at six locations in North America.
North America contributed roughly a quarter (23%) to Evonik’s annual sales in 2021, making it the second-largest revenue source after Europe. By 2030, Evonik aims to invest more than $3 billion in Next Generation Solutions — products with superior sustainability benefits. Evonik will invest an additional $700 million in Next Generation Technologies to optimize production processes and infrastructure and avoid CO2 emissions.
Evonik’s medical polymers portfolio includes bioresorbable, permanent implant and temporary contact materials for medical device technologies, including VESTAKEEP PEEK, suitable for implant devices used in the orthopedic, spine, sports medicine and extremities markets.
“For Evonik, moving towards a hybrid workplace is a strategic opportunity to attract and retain diverse talent and to enable an efficient real estate footprint,” says Bonnie Tully, president North America region. “We want to foster conditions for growth, creativity, and innovation.”
Source: Evonik
